GlassScriptPhysician profile
Erik Person
NPI 1609003912
$14,739.56
in general payments reported to CMS, 2019-2025
42 companies · $3,494 in 2025
The $3,494 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,283 · 2020: $872 · 2021: $1,412 · 2022: $2,352 · 2023: $2,297 · 2024: $3,029 · 2025: $3,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,763 · Education: $57.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,762.71 |
| Education | $57.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,695.97 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,794.81 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,142.09 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,047.59 | 2019-2025 | Stelara, Tremfya |
| Ardelyx, INC. | $687.24 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $650.87 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $646.66 | 2022-2025 | Dupixent |
| Pfizer INC. | $518.22 | 2019-2025 | |
| Celgene Corporation | $493.09 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $461.40 | 2019-2024 | Ocaliva |
| Gilead Sciences, INC. | $339.41 | 2019-2025 | Livdelzi |
| Ucb, INC. | $313.25 | 2019-2021 | |
| Madrigal Pharmaceuticals | $300.75 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $293.23 | 2023-2025 | Omvoh, Zepbound |
| Ipsen Biopharmaceuticals, INC | $273.34 | 2024-2025 | Iqirvo |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $250.46 | 2019-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $240.53 | 2019-2023 | Dificid |
| Ironwood Pharmaceuticals, INC | $165.66 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $160.56 | 2025 | Terlivaz |
| Boston Scientific Corporation | $154.15 | 2025 | Watchman Flx, General - Therapies |
| Ferring Pharmaceuticals INC. | $127.71 | 2020-2025 | Rebyota |
| Celltrion USA INC. | $114.33 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Janssen Scientific Affairs, LLC | $84.85 | 2019 | |
| Phathom Pharmaceuticals, INC. | $81.87 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $79.15 | 2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $76.65 | 2020-2022 | |
| Vivus LLC | $71.81 | 2025 | Pancreaze |
| Amgen INC. | $69.95 | 2023 | Amjevita, Avsola |
| Braintree Laboratories, INC. | $58.07 | 2021-2025 | Suflave, Sutab |
| Organon LLC | $38.60 | 2024-2025 | Renflexis, Hadlima |
| Sandoz INC. | $37.59 | 2023-2024 | Hyrimoz |
| Novo Nordisk INC | $36.58 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $33.56 | 2024-2025 | Zenpep |
| Romark Laboratories, Lc | $33.48 | 2019-2020 | |
| Evoke Pharma, INC. | $31.73 | 2021-2023 | Gimoti |
| Fresenius Kabi USA, LLC | $31.56 | 2023 | |
| Shionogi INC | $30.83 | 2019 | |
| Daiichi Sankyo INC. | $23.97 | 2020 | |
| Medtronic, INC. | $13.77 | 2025 | Interstim |
| Redhill Biopharma INC. | $11.99 | 2020 | |
| Endo Pharmaceuticals INC. | $11.88 | 2019 | |
| Mauna Kea Technologies, INC. | $10.35 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Person listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.